Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venlafaxine vs ACT+CFT for depression, stress, and anxiety in methadone-maintained patients
IRCT20191106045356N3Phase 3Completed
- Sponsor
- Shahid Sadoughi University of Medical Sciences
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of venlafaxine in major depressive disorder (MDD), anxiety disorder, chronic stress and 1 more (2 arms), sponsored by Shahid Sadoughi University of Medical Sciences. Primary endpoints: Change in depression, Change in anxiety and 1 more. Started May 2021; status: completed.
02
Drugs
venlafaxine
03
Conditions
major depressive disorder (MDD)anxiety disorderchronic stressopioid use disorder (OUD)
Beyond the preview
Go deeper on IRCT20191106045356N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191106045356N3.